{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:58:27Z","timestamp":1781074707582,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00228-026-04090-y","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:36:03Z","timestamp":1780457763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics of lumefantrine in pregnant and non-pregnant Nigerian women receiving efavirenz-based antiretroviral therapy"],"prefix":"10.1007","volume":"82","author":[{"given":"Tawakalt Olamide","family":"Akinrinade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Adebayo","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-2641","authenticated-orcid":false,"given":"Adebanjo Jonathan","family":"Adegbola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekemi","family":"Adeleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta Nwamaka","family":"Nwogu-Attah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwasegun","family":"Eniayewu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayorinde","family":"Adehin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluseye Oladotun","family":"Bolaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"4090_CR1","unstructured":"WHO (2025) World malaria report 2025: addressing the threat of antimalarial drug resistance. In: ed. World Health Organization"},{"key":"4090_CR2","doi-asserted-by":"publisher","unstructured":"Berhe AD, Doritchamou JYA, Duffy PE (2023) Malaria in pregnancy: adverse pregnancy outcomes and the future of prevention. Front Trop Dis Volume 4\u20132023. https:\/\/doi.org\/10.3389\/fitd.2023.1229735","DOI":"10.3389\/fitd.2023.1229735"},{"issue":"1","key":"4090_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12936-017-2040-4","volume":"16","author":"J Kapisi","year":"2017","unstructured":"Kapisi J, Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Ssekitoleko R, Olwoch P, Ategeka J, Nayebare P, Clark TD, Rizzuto G, Muehlenbachs A, Havlir DV, Kamya MR, Dorsey G, Gaw SL (2017) Relationships between infection with Plasmodium falciparum during pregnancy, measures of placental malaria, and adverse birth outcomes. Malar J 16(1):400. https:\/\/doi.org\/10.1186\/s12936-017-2040-4","journal-title":"Malar J"},{"issue":"13","key":"4090_CR4","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/1873-3468.12151","volume":"590","author":"F Frischknecht","year":"2016","unstructured":"Frischknecht F, Fackler OT (2016) Experimental systems for studying Plasmodium\/HIV coinfection. FEBS Lett 590(13):2000\u20132013","journal-title":"FEBS Lett"},{"key":"4090_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/rrtm.s154501","volume":"9","author":"TE Kwenti","year":"2018","unstructured":"Kwenti TE (2018) Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and treatment strategies. Res Rep Trop Med 9:123\u2013136. https:\/\/doi.org\/10.2147\/rrtm.s154501","journal-title":"Res Rep Trop Med"},{"issue":"2","key":"4090_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bcp.14474","volume":"88","author":"B Hanboonkunupakarn","year":"2022","unstructured":"Hanboonkunupakarn B, White NJ (2022) Advances and roadblocks in the treatment of malaria. Br J Clin Pharmacol 88(2):374\u2013382. https:\/\/doi.org\/10.1111\/bcp.14474","journal-title":"Br J Clin Pharmacol"},{"key":"4090_CR7","unstructured":"WHO (2024) Guidelines for malaria: WHO Guidelines for malaria. In: ed. World Health Organization"},{"issue":"1","key":"4090_CR8","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1186\/s12879-025-12130-8","volume":"25","author":"FET Bohissou","year":"2025","unstructured":"Bohissou FET, Nassa GJW, Sondo P, Rouamba T, Inoue J, Kabor\u00e9 B, Asua V, Held J, Tinto H (2025) Spatio-temporal trends of artemisinin-based combination therapy efficacy from 2010 to 2024 in sub-Saharan Africa: a systematic review and meta-analysis. BMC Infect Dis 25(1):1684. https:\/\/doi.org\/10.1186\/s12879-025-12130-8","journal-title":"BMC Infect Dis"},{"key":"4090_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.70072","volume-title":"Artemisinin-Based Combination Therapies in East Africa: A Systematic Review of Quality, Clinical Efficacy, and Regulatory Progress Towards Sustainable Malaria Control","author":"YT Mekasha","year":"2025","unstructured":"Mekasha YT, Tegegne AA, Mashe T, Girma M, Hasen G, Belew S (2025) Artemisinin-Based Combination Therapies in East Africa: A Systematic Review of Quality, Clinical Efficacy, and Regulatory Progress Towards Sustainable Malaria Control. TM & IH, Tropical medicine & international health. https:\/\/doi.org\/10.1111\/tmi.70072"},{"key":"4090_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2147\/tcrm.s336771","volume":"17","author":"W Shibeshi","year":"2021","unstructured":"Shibeshi W, Baye AM, Alemkere G, Engidawork E (2021) Efficacy and Safety of Artemisinin-Based Combination Therapy for the Treatment of Uncomplicated Malaria in Pregnant Women: A Systematic Review and Meta-Analysis. Ther Clin Risk Manag 17:1353\u20131370. https:\/\/doi.org\/10.2147\/tcrm.s336771","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"4090_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1186\/s12879-025-11704-w","volume":"25","author":"AA Ahmed","year":"2025","unstructured":"Ahmed AA, Bello IS, Adewole TO, Olowookere SA, Oyegbade OO, Ogundokun AO, Olajubu TO, Funwei RI, Ojurongbe O, Adepoju DA, Bello AB, Adegboyega AA, Anjorin AO, Anjorin AO, Akinola OO, Adewumi KM, Omenugha MK, Salami OT, Familusi AO, Akande EO (2025) Parasite clearance of two commonly administered artemisinin-based combination therapies in under-five children with uncomplicated malaria in a comprehensive healthcare facility in South-Western Nigeria: a randomised controlled trial. BMC Infect Dis 25(1):1403. https:\/\/doi.org\/10.1186\/s12879-025-11704-w","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4090_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12936-025-05576-3","volume":"24","author":"VS Koko","year":"2025","unstructured":"Koko VS, Skrip L, Kumeh O, Washington T, Diallo MO, Kafuko J, Inyang U, Ponce de Le\u00f3n GF, Zhou Z, Laird VR, Zawolo J, Getahun B, Harmon-Gray WM, Plucinski M, Schultz JS (2025) Efficacy and safety of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated Plasmodium falciparum malaria in Liberia, 2022\u20132023. Malar J 24(1):319. https:\/\/doi.org\/10.1186\/s12936-025-05576-3","journal-title":"Malar J"},{"key":"4090_CR13","doi-asserted-by":"crossref","unstructured":"Okanlawon BM, Ojeniyi FD, Mbabie UC, Obasa OJ, Olorunfemi AB, Akindele AA, Akinola O, Ojurongbe O (2025) Evaluating the efficacy of Artemisinin - based combination therapies for treating plasmodium falciparum among children in Osogbo, Nigeria: a study conducted 13 years after ACT introduction. Pan Afr J Life Sci 9(2):418\u2013432","DOI":"10.36108\/pajols\/5202\/90.0230"},{"key":"4090_CR14","unstructured":"WHO (2024) Multiple first-line therapies as part of the response to antimalarial drug resistance: an implementation guide. In: ed. World Health Organization, p 38"},{"issue":"7","key":"4090_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jcph.6193","volume":"65","author":"ME Whalen","year":"2025","unstructured":"Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Hoffmann TJ, Aweeka FT, Parikh S, Mwebaza N (2025) Extended Treatment Duration of Artemether-Lumefantrine in Ugandan Children with HIV on Efavirenz-Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial. J Clin Pharmacol 65(7):909\u2013922. https:\/\/doi.org\/10.1002\/jcph.6193","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"4090_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12936-019-2818-7","volume":"18","author":"CG Banda","year":"2019","unstructured":"Banda CG, Chaponda M, Mukaka M, Mulenga M, Hachizovu S, Kabuya JB, Mulenga J, Sikalima J, Kalilani-Phiri L, Terlouw DJ, Khoo SH, Lalloo DG, Mwapasa V (2019) Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial. Malar J 18(1):180. https:\/\/doi.org\/10.1186\/s12936-019-2818-7","journal-title":"Malar J"},{"issue":"1","key":"4090_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12936-025-05393-8","volume":"24","author":"A Takyi","year":"2025","unstructured":"Takyi A, Soma A, Przybylska M, Harriss E, Barnes KI, Dahal P, Gu\u00e9rin PJ, Stepniewska K, Carrara VI (2025) Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review. Malar J 24(1):153. https:\/\/doi.org\/10.1186\/s12936-025-05393-8","journal-title":"Malar J"},{"key":"4090_CR18","doi-asserted-by":"publisher","unstructured":"Adegbola A, Abutaima R, Olagunju A, Ijarotimi O, Siccardi M, Owen A, Soyinka J, Bolaji O (2018) Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. Antimicrob Agents Chemother 62(10). https:\/\/doi.org\/10.1128\/aac.01252-18","DOI":"10.1128\/aac.01252-18"},{"key":"4090_CR19","doi-asserted-by":"publisher","unstructured":"Walimbwa SI, Lamorde M, Waitt C, Kaboggoza J, Else L, Byakika-Kibwika P, Amara A, Gini J, Winterberg M, Chiong J, Tarning J, Khoo SH (2019) Drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine. Antimicrob Agents Chemother 63(2). https:\/\/doi.org\/10.1128\/aac.01310-18","DOI":"10.1128\/aac.01310-18"},{"issue":"1","key":"4090_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12981-025-00787-9","volume":"22","author":"NE Thomford","year":"2025","unstructured":"Thomford NE, Kellermann T, Twum JA, Anyimadu J, Dixon C, Sappor D, Blackhurst D, Barnie PA, Ryabinina O, Nyarko SB, Biney RP, Ekor M, Kyei GB (2025) Drug-drug interaction between dolutegravir and artemether-lumefantrine in HIV and malaria mono- and co-infections: a pharmacogenetic analysis from Ghana. AIDS Res Therapy 22(1):85. https:\/\/doi.org\/10.1186\/s12981-025-00787-9","journal-title":"AIDS Res Therapy"},{"key":"4090_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.actatropica.2017.12.021","volume":"179","author":"AE Zautner","year":"2018","unstructured":"Zautner AE, Herchenr\u00f6der O, Moussi AE, Schwarz NG, Wiemer DF, Gro\u00df U, Frickmann H (2018) Pharmaceutical interactions between antiretroviral and antimalarial drugs used in chemoprophylaxis. Acta Trop 179:25\u201335. https:\/\/doi.org\/10.1016\/j.actatropica.2017.12.021","journal-title":"Acta Trop"},{"issue":"1","key":"4090_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12916-020-1494-3","volume":"18","author":"MT Bretscher","year":"2020","unstructured":"Bretscher MT, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D\u2019Alessandro U, Djimde AA, Dorsey G, Espi\u00e9 E, Fofana B, Gonz\u00e1lez R, Juma E, Karema C, Lasry E, Lell B, Lima N, Men\u00e9ndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ou\u00e9draogo JB, Staedke SG, Tinto H, Valea I, Yeka A, Ghani AC, Guerin PJ, Okell LC (2020) The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Med 18(1):47. https:\/\/doi.org\/10.1186\/s12916-020-1494-3","journal-title":"BMC Med"},{"key":"4090_CR23","doi-asserted-by":"publisher","unstructured":"Djimd\u00e9 A, Lef\u00e8vre G (2009) Understanding the pharmacokinetics of Coartem. Malar J 8 Suppl (Suppl 1): S 4(1). https:\/\/doi.org\/10.1186\/1475-2875-8-s1-s4","DOI":"10.1186\/1475-2875-8-s1-s4"},{"issue":"1","key":"4090_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12936-024-04930-1","volume":"23","author":"NE Thomford","year":"2024","unstructured":"Thomford NE, Kellermann T, Biney RP, Dixon C, Nyarko SB, Ateko RO, Ekor M, Kyei GB (2024) Therapeutic efficacy of generic artemether-lumefantrine in the treatment of uncomplicated malaria in Ghana: assessing anti-malarial efficacy amidst pharmacogenetic variations. Malar J 23(1):125. https:\/\/doi.org\/10.1186\/s12936-024-04930-1","journal-title":"Malar J"},{"issue":"1","key":"4090_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12936-024-05088-6","volume":"23","author":"KM Oyebola","year":"2024","unstructured":"Oyebola KM, Ligali FC, Owoloye AJ, Aina OO, Alo YM, Erinwusi B, Olufemi MJ, Salako BL (2024) Assessing the therapeutic efficacy of artemether-lumefantrine for uncomplicated malaria in Lagos, Nigeria: a comprehensive study on treatment response and resistance markers. Malar J 23(1):261. https:\/\/doi.org\/10.1186\/s12936-024-05088-6","journal-title":"Malar J"},{"issue":"1","key":"4090_CR26","doi-asserted-by":"publisher","first-page":"7371681","DOI":"10.1155\/2020\/7371681","volume":"200","author":"A Derbie","year":"2020","unstructured":"Derbie A, Mekonnen D, Adugna M, Yeshitela B, Woldeamanuel Y, Abebe T (2020) Therapeutic efficacy of artemether-lumefantrine (Coartem\u00ae) for the treatment of uncomplicated falciparum malaria in Africa: A systematic review. J Parasitol Res 2020(1):7371681. https:\/\/doi.org\/10.1155\/2020\/7371681","journal-title":"J Parasitol Res"},{"issue":"1","key":"4090_CR27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12936-025-05679-x","volume":"24","author":"IM Laminou","year":"2025","unstructured":"Laminou IM, Kabirou SM, Arzika II, Yahaya A, Ahmed J, Deme AB, Diallo MA, Ngom B, Gaye A, Sene A, Sow D, Coulibaly E, Bahari-Tohon Z, Sanoussi E, Koko D, Cavros I (2025) Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial resistance in Niger, 2022. Malar J 24(1):448. https:\/\/doi.org\/10.1186\/s12936-025-05679-x","journal-title":"Malar J"},{"issue":"4","key":"4090_CR28","doi-asserted-by":"publisher","first-page":"e0176004","DOI":"10.1371\/journal.pone.0176004","volume":"12","author":"M Teklemariam","year":"2017","unstructured":"Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H (2017) Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. PLoS ONE 12(4):e0176004. https:\/\/doi.org\/10.1371\/journal.pone.0176004","journal-title":"PLoS ONE"},{"issue":"1","key":"4090_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12916-015-0456-7","volume":"13","author":"WorldWide Antimalarial Resistance Network Lumefantrine PKPDSG","year":"2015","unstructured":"WorldWide Antimalarial Resistance Network Lumefantrine PKPDSG (2015) Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med 13(1):227. https:\/\/doi.org\/10.1186\/s12916-015-0456-7","journal-title":"BMC Med"},{"issue":"3","key":"4090_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cid\/ciac783","volume":"76","author":"ME Whalen","year":"2023","unstructured":"Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S (2023) The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clin Infect diseases: official publication Infect Dis Soc Am 76(3):443\u2013452. https:\/\/doi.org\/10.1093\/cid\/ciac783","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"key":"4090_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijid.2022.08.020","volume":"123","author":"KJ Marwa","year":"2022","unstructured":"Marwa KJ, Liwa AC, Konje ET, Mwita S, Kamugisha E, Swedberg G (2022) Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza. Tanzan Int J Infect diseases: IJID : official publication Int Soc Infect Dis 123:192\u2013199. https:\/\/doi.org\/10.1016\/j.ijid.2022.08.020","journal-title":"Tanzan Int J Infect diseases: IJID : official publication Int Soc Infect Dis"},{"key":"4090_CR32","doi-asserted-by":"publisher","unstructured":"Onyamboko MA, Hoglund RM, Lee SJ, Kabedi C, Kayembe D, Badjanga BB, Turner GDH, Jackson NV, Tarning J, McGready R, Nosten F, White NJ, Day NPJ, Fanello C (2020) A randomized controlled trial of three- versus five-day artemether-lumefantrine regimens for treatment of uncomplicated plasmodium falciparum malaria in pregnancy in Africa. Antimicrob Agents Chemother 64(3). https:\/\/doi.org\/10.1128\/aac.01140-19","DOI":"10.1128\/aac.01140-19"},{"key":"4090_CR33","doi-asserted-by":"publisher","unstructured":"Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, Bygbjerg IC, Parikh S, Aweeka FT, Tarning J, Denti P (2020) An individual participant data population pharmacokinetic meta-analysis of drug-drug interactions between lumefantrine and commonly used antiretroviral treatment. Antimicrob Agents Chemother 64(5). https:\/\/doi.org\/10.1128\/aac.02394-19","DOI":"10.1128\/aac.02394-19"},{"issue":"18","key":"4090_CR34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2217\/pgs-2020-0081","volume":"21","author":"AJ Adegbola","year":"2020","unstructured":"Adegbola AJ, Soyinka JO, Bolaji OO (2020) Effect of CYP3A5*3 genotypes on lumefantrine plasma concentrations among malaria-HIV-infected women. Pharmacogenomics 21(18):1289\u20131297. https:\/\/doi.org\/10.2217\/pgs-2020-0081","journal-title":"Pharmacogenomics"},{"key":"4090_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.70318","author":"E Juma","year":"2025","unstructured":"Juma E, Ding J, Ongas M, Koskei N, Onyango K, Oloo F, Aman R, Kokwaro G, Tarning J, Ogutu B (2025) Population pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Western Kenya. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.70318","journal-title":"Br J Clin Pharmacol"},{"key":"4090_CR36","doi-asserted-by":"publisher","unstructured":"Lohy Das J, Rulisa S, de Vries PJ, Mens PF, Kaligirwa N, Agaba S, Tarning J, Karlsson MO, Dorlo TPC (2018) Population pharmacokinetics of artemether, dihydroartemisinin, and lumefantrine in rwandese pregnant women treated for uncomplicated plasmodium falciparum malaria. Antimicrob Agents Chemother 62(10). https:\/\/doi.org\/10.1128\/aac.00518","DOI":"10.1128\/aac.00518"},{"issue":"2","key":"4090_CR37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/bcp.70301","volume":"92","author":"J Ding","year":"2026","unstructured":"Ding J, Hoglund RM, van der Pluijm RW, Callery JJ, Peto TJ, Tripura R, Das S, Ch\u00e2u NH, Promnarate C, Mukaka M, Dysoley L, Fanello C, Onyamboko MA, Anvikar AR, Mayxay M, Smithuis F, von Seidlein L, Dhorda M, Amaratunga C, Faiz MA, Nghia HDT, White NJ, Day NPJ, Dondorp AM, Tarning J (2026) Population pharmacokinetics of artemether\u2013lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria. Br J Clin Pharmacol 92(2):589\u2013605. https:\/\/doi.org\/10.1002\/bcp.70301","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4090_CR38","doi-asserted-by":"publisher","first-page":"e1002579","DOI":"10.1371\/journal.pmed.1002579","volume":"15","author":"F Kloprogge","year":"2018","unstructured":"Kloprogge F, Workman L, Borrmann S, T\u00e9k\u00e9t\u00e9 M, Lef\u00e8vre G, Hamed K, Piola P, Ursing J, Kofoed PE, M\u00e5rtensson A, Ngasala B, Bj\u00f6rkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J (2018) Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med 15(6):e1002579. https:\/\/doi.org\/10.1371\/journal.pmed.1002579","journal-title":"PLoS Med"},{"issue":"3","key":"4090_CR39","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1128\/aac.01605-15","volume":"60","author":"MM Nyunt","year":"2015","unstructured":"Nyunt MM, Nguyen VK, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Mwima MW, Achan J, Aweeka F, Parikh S, Mwebaza N (2015) Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrob Agents Chemother 60(3):1274\u20131282. https:\/\/doi.org\/10.1128\/aac.01605-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4090_CR40","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1128\/aac.02595-14","volume":"58","author":"D Mosha","year":"2014","unstructured":"Mosha D, Guidi M, Mwingira F, Abdulla S, Mercier T, Decosterd LA, Csajka C, Genton B (2014) Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. Antimicrob Agents Chemother 58(8):4583\u20134592. https:\/\/doi.org\/10.1128\/aac.02595-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4090_CR41","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1038\/psp.2013.59","volume":"2","author":"F Kloprogge","year":"2013","unstructured":"Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Apinan S, Lindeg\u00e5rdh N, Nosten F, Day NP, White NJ, Guerin PJ, Tarning J (2013) Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. CPT Pharmacometrics Syst Pharmacol 2(11):e83. https:\/\/doi.org\/10.1038\/psp.2013.59","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"4090_CR42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/aac.44.3.697-704.2000","volume":"44","author":"F Ezzet","year":"2000","unstructured":"Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ (2000) Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 44(3):697\u2013704. https:\/\/doi.org\/10.1128\/aac.44.3.697-704.2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4090_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/FPC.0000000000000401","volume":"30","author":"AJ Adegbola","year":"2020","unstructured":"Adegbola AJ, Rana A, Adeagbo BA, Bolarinwa RA, Olagunju AE, Siccardi M, Owen A, Bolaji OO (2020) Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. Pharmacogenet Genomics 30(5):96\u2013106","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"4090_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12936-020-03287-5","volume":"19","author":"LE Mhamilawa","year":"2020","unstructured":"Mhamilawa LE, Ngasala B, Morris U, Kitabi EN, Barnes R, Soe AP, Mmbando BP, Bj\u00f6rkman A, M\u00e5rtensson A (2020) Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial. Malar J 19(1):216. https:\/\/doi.org\/10.1186\/s12936-020-03287-5","journal-title":"Malar J"},{"issue":"11","key":"4090_CR45","doi-asserted-by":"publisher","first-page":"ofae627","DOI":"10.1093\/ofid\/ofae627","volume":"11","author":"S Simeon","year":"2024","unstructured":"Simeon S, Hughes E, Wallender E, B PS, Savic R (2024) Optimizing lumefantrine dosing for young children in high-malaria-burden countries using pharmacokinetic-pharmacodynamic simulations. Open forum Infect Dis 11(11):ofae627. https:\/\/doi.org\/10.1093\/ofid\/ofae627","journal-title":"Open forum Infect Dis"},{"issue":"1","key":"4090_CR46","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1038\/s41467-024-48210-7","volume":"15","author":"J Goodwin","year":"2024","unstructured":"Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka FT, Mwebaza N, Parikh S (2024) Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nat Commun 15(1):3817. https:\/\/doi.org\/10.1038\/s41467-024-48210-7","journal-title":"Nat Commun"},{"issue":"8","key":"4090_CR47","doi-asserted-by":"publisher","first-page":"e0087321","DOI":"10.1128\/aac.00873-21","volume":"65","author":"KB Beshir","year":"2021","unstructured":"Beshir KB, Diallo N, Som\u00e9 FA, Sombie S, Zongo I, Fofana B, Traore A, Dama S, Bamadio A, Traore OB, Coulibaly SA, Maurice OS, Diarra A, Kabor\u00e9 JM, Kodio A, Togo AH, Dara N, Coulibaly M, Dao F, Nikiema F, Compaore YD, Kabore NT, Barry N, Soulama I, Sagara I, Sirima SB, Ou\u00e9draogo JB, Djimde A, Sutherland CJ (2021) Persistent submicroscopic plasmodium falciparum parasitemia 72 hours after treatment with artemether-lumefantrine predicts 42-day treatment failure in Mali and Burkina Faso. Antimicrob Agents Chemother 65(8):e0087321. https:\/\/doi.org\/10.1128\/aac.00873-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4090_CR48","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12936-020-03309-2","volume":"19","author":"LE Mhamilawa","year":"2020","unstructured":"Mhamilawa LE, Wikstr\u00f6m S, Mmbando BP, Ngasala B, M\u00e5rtensson A (2020) Electrocardiographic safety evaluation of extended artemether-lumefantrine treatment in patients with uncomplicated Plasmodium falciparum malaria in Bagamoyo District, Tanzania. Malar J 19(1):250. https:\/\/doi.org\/10.1186\/s12936-020-03309-2","journal-title":"Malar J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04090-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04090-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04090-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:17:12Z","timestamp":1781072232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04090-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4090"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04090-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared that ethics approval was provided by the Health Research and Ethics Committee of Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife (ERC\/2016\/03\/11). The informed consent form for this study was approved by the Ethics committee as stated above.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declared that study participants for Pharmacokinetic data collection voluntarily agreed to participate in the study. Volunteers provided written informed consent, and all protocols followed the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}